Inactive Instrument

IPI Legacy Liquidation Co

Equities

IMPL

US45258K1097

Biotechnology & Medical Research

Impel Pharmaceuticals Inc. Announces Stephen Shrewsbury, Chief Medical Officer Will Depart from the Company Effective March 31, 2023

February 22, 2023 at 04:30 pm

Impel Pharmaceuticals Inc. announced that Stephen Shrewsbury, M.D., current Chief Medical Officer, will depart from the Company effective March 31, 2023.

Latest news about IPI Legacy Liquidation Co

North American Morning Briefing : Big Banks Kick -2-	04-12	DJ
North American Morning Briefing : Investors on -2-	04-05	DJ
IPI Legacy Liquidation Co Went Out of Business	04-05	CI
Second Revised First Amended Liquidation Plan Approved for IPI Legacy Liquidation Co	04-02	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
Impel Pharmaceuticals Inc. has Changed its Name to IPI Legacy Liquidation Co	03-08	CI
Combined Disclosure Statement Conditionally Approved for Impel Pharmaceuticals Inc.	02-26	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Impel Pharmaceuticals Inc.	02-25	CI
Impel Pharmaceuticals Inc. Announces Departure of Len Paolillo as Interim Chief Executive Officer	02-14	CI
Joint Liquidation Plan and Disclosure Statement Filed by Impel Pharmaceuticals Inc.	02-12	CI
An undisclosed buyer completed the acquisition of substantially all assets of Impel Pharmaceuticals Inc. for $17.5 million.	02-11	CI
Motion for Asset Sale Approved for Impel Pharmaceuticals Inc.	02-02	CI
Notice of Winning Bidder Filed by Impel Pharmaceuticals Inc.	01-29	CI
Notice of Auction Cancellation Filed by Impel Pharmaceuticals Inc.	01-26	CI
Bidding Procedure Approved for Impel Pharmaceuticals Inc.	01-10	CI
Motion for Joint Administration Approved for Impel Pharmaceuticals Inc.	12-20	CI
Impel Pharmaceuticals Inc. Appoints Brandon Smith as Chief Restructuring Officer	12-20	CI
Impel Pharmaceuticals Files for Chapter 11 to Facilitate Sale	12-20	CI
Motion for Asset Sale Filed by Impel Pharmaceuticals Inc.	12-20	CI
Impel Pharmaceuticals Inc.(NasdaqGM:IMPL) dropped from S&P TMI Index	12-20	CI
Impel Pharmaceuticals Inc. Filed for Bankruptcy	12-19	CI
Motion for Joint Administration Filed by Impel Pharmaceuticals Inc.	12-18	CI
An undisclosed buyer entered into an agreement to acquire substantially all assets of Impel Pharmaceuticals Inc. for $17.5 million.	12-18	CI
Impel Pharmaceuticals Inc.(OTCPK:IMPL) dropped from NASDAQ Composite Index	12-15	CI
Impel Pharmaceuticals Inc. Announces Resignation of Michael Kalb as Chief Financial Officer, Effective on December 31, 2023	12-04	CI

Chart IPI Legacy Liquidation Co

Duration

Period

More charts

Company Profile

IPI Legacy Liquidation Co, formerly Impel Pharmaceuticals Inc., is not engaged in any business operations. The Company doesnât hold any assets.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+52.36%	56.69B
IQVIA HOLDINGS INC.	-3.86%	41B
LONZA GROUP AG	+38.14%	38.11B
CELLTRION, INC.	-12.01%	26.89B
ICON PUBLIC LIMITED COMPANY	+14.13%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.62%	18.59B
BIO-TECHNE CORPORATION	+0.21%	12.39B
MEDPACE HOLDINGS, INC.	+25.96%	11.99B
UNITED THERAPEUTICS CORPORATION	+23.02%	11.88B

Other Biotechnology & Medical Research